2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 46-53

  Li, Meng ^a   Wu, Yaomin ^a   Qiu, Yuhe ^a   Yao, Zhenyu ^a   Liu, Shilian ^a   Liu, Yanxin ^a   Shi, Juan ^a   Zheng, Dexian ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 5; LENTIVIRUS VECTOR; MITOMYCIN C; UNCLASSIFIED DRUG; ZAPTUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

LENTIVIRUS; MUS MUSCULUS;

EID: 84856954243     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.197     Document Type: Article

References (29)

1. Wiley, SR, Schooley, K, Smolak, PJ, Din, WS, Huang, CP, Nicholl, JK et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682. (Pubitemid 26091143)
2. Ashkenazi, A, Pai, RC, Fong, S, Leung, S, Lawrence, DA, Marsters, SA et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
3. Walczak, H, Miller, RE, Ariail, K, Gliniak, B, Griffith, TS, Kubin, M et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163. (Pubitemid 29068521)
4. Bellail, AC, Qi, L, Mulligan, P, Chhabra, V and Hao, C (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4: 34-41.
5. Forero-Torres, A, Shah, J, Wood, T, Posey, J, Carlisle, R, Copigneaux, C et al. (2010). Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25: 13-19.
6. Guo, Y, Chen, C, Zheng, Y, Zhang, J, Tao, X, Liu, S et al. (2005). A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 280: 41940-41952. (Pubitemid 43023163)
7. Zhang, P, Zheng, Y, Shi, J, Zhang, Y, Liu, S, Liu, Y et al. (2010). Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death. J Biol Chem 285: 8953-8966.
8. Carter, PJ (2006). Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357.
9. Shi, J, Liu, Y, Zheng, Y, Guo, Y, Zhang, J, Cheung, PT et al. (2006). Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res 66: 11946-11953. (Pubitemid 46094208)
10. Fang, J, Qian, JJ, Yi, S, Harding, TC, Tu, GH, VanRoey, M et al. (2005). Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590. (Pubitemid 41724897)
11. Li, M, Lu, FJ, Shi, J, Liu, YX and Zheng, DX (2011). Expression and tumoricidal activity of a human-mouse chimeric anti-DR5 antibody through a Furin/2A peptide. Zonghua Yi Xue Za Zhi 91: 707-710. [Chinese].
12. Shi, J, Zheng, D, Liu, Y, Sham, MH, Tam, P, Farzaneh, F et al. (2005). Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 65: 1687-1692. (Pubitemid 40478593)
13. Tjelle, TE, Corthay, A, Lunde, E, Sandlie, I, Michaelsen, TE, Mathiesen, I et al. (2004). Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 9: 328-336. (Pubitemid 38404521)
14. Ho, DT, Wykoff-Clary, S, Gross, CS, Schneider, D, Jin, F, Kretschmer, PJ et al. (2009). Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther 16: 184-194.
15. Wang, G, Qiu, J, Wang, R, Krause, A, Boyer, JL, Hackett, NR et al. (2010). Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 17: 559-570.
16. Mizuguchi, H, Xu, Z, Ishii-Watabe, A, Uchida, E and Hayakawa, T (2000). IRESdependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376-382.
17. Hale, G, Berrie, E and Bird, P (2004). Design and manufacture of monoclonal antibodies for radioimmunotherapy. Q J Nucl Med Mol Imaging 48: 258-266. (Pubitemid 43932935)
18. Fang, J, Yi, S, Simmons, A, Tu, GH, Nguyen, M, Harding, TC et al. (2007). An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 15: 1153-1159. (Pubitemid 46813618)
19. Naldini, L, Bler, U, Gage, FH, Trono, D and Verma, IM (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93: 11382-11388. (Pubitemid 26347130)
20. Kafri, T, Bler, U, Peterson, DA, Gage, FH and Verma, IM (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 17: 314-317. (Pubitemid 27475995)
21. Naldini, L, Bler, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267. (Pubitemid 26119138)
22. Reiser, J, Zhang, XY, Hemenway, CS, Mondal, D, Pradhan, L and La Russa, VF (2005). Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 5: 1571-1584. (Pubitemid 41771848)
23. Kock, N, Kasmieh, R, Weissleder, R and Shah, K (2007). Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 9: 435-442. (Pubitemid 46799987)
24. Zhang, X, Zhao, P, Kennedy, C, Chen, K, Wiegand, J, Washington, G et al. (2008). Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther 15: 73-84.
25. Bardella, C, Dettori, D, Olivero, M, Coltella, N, Mazzone, M and Di Renzo, MF (2007). The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 13: 2191-2198. (Pubitemid 46649889)
26. Visigalli, I, Delai, S, Politi, LS, Di Domenico, C, Cerri, F, Mrak, E et al. (2010). Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116: 5130-5139.
27. Carmo, M, Alves, A, Rodrigues, AF, Coroadinha, AS, Carrondo, MJ, Alves, PM et al. (2009). Stabilization of gammaretroviral and lentiviral vectors: from production to gene transfer. J Gene Med 11: 670-678.
28. Krueger, A, Baumann, S, Krammer, PH and Kirchhoff, S (2001). FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254. (Pubitemid 33108586)
29. Wu, H, Tschopp, J and Lin, SC (2007). Smac mimetics and TNFalpha: a dangerous liaisonÁ Cell 131: 655-658. (Pubitemid 350087206)